On Friday, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) was -10.45% drop from the session before settling in for the closing price of $1.77. A 52-week range for IRWD has been $0.53 – $5.13.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -47.49%. When this article was written, the company’s average yearly earnings per share was at 1815.20%. With a float of $156.35 million, this company’s outstanding shares have now reached $162.43 million.
Ironwood Pharmaceuticals Inc (IRWD) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ironwood Pharmaceuticals Inc stocks. The insider ownership of Ironwood Pharmaceuticals Inc is 3.74%, while institutional ownership is 90.40%. The most recent insider transaction that took place on Aug 11 ’25, was worth 1,105. In this transaction Chief Commercial Officer of this company sold 1,316 shares at a rate of $0.84, taking the stock ownership to the 241,280 shares. Before that another transaction happened on Aug 11 ’25, when Company’s Chief Legal Officer sold 7,754 for $0.84, making the entire transaction worth $6,513. This insider now owns 400,378 shares in total.
Ironwood Pharmaceuticals Inc (IRWD) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 0.02 earnings per share (EPS) during the time that was less than consensus figure (set at 0.1) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1815.20% per share during the next fiscal year.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Trading Performance Indicators
You can see what Ironwood Pharmaceuticals Inc (IRWD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83. Likewise, its price to free cash flow for the trailing twelve months is 8.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.05, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.40 in one year’s time.
